Skip to main content

Table 1 Summary of results of potential makers validated using a targeted proteomic mass spectrometry test

From: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

Alzheimer’s disease Lewy body dementia Parkinson’s disease
Protein biomarker Fold-change (statistical significance) Protein biomarker Fold-change (statistical significance) Protein biomarker Fold-change (statistical significance)
Osteopontin 4.7 (p < 0.002)    DJ1 3.1 (p < 0.0053)
   Osteopontin 2.3 (p < 0.02) aMalate dehydrogenase 2.2 (not significant)
CNDP1 3.2 (p < 0.0001) aUCHL1 2.2 (p < 0.01) aLSAMP 1.9 (p < 0.0136)
aMalate dehydrogenase 3.2 (p < 0.0001) Chitinase-3-like protein 1 2.1 (p < 0.0004) Apolipoprotein H 1.8 (p < 0.0484)
Apolipoprotein E 2.9 (p < 0.0001) aGM2 Activator Protein 1.9 (p < 0.0087) Serum Amyloid A4 1.7 (not significant)
Ubiquitin 2.3 (p < 0.0015) aMalate dehydrogenase 1.9 (p < 0.0082) Pro-orexin 1.6 (not significant)
aGM2 Activator Protein 2.3 (p < 0.0002) aSerum Amyloid A4 1.9 (p < 0.0092) Osteopontin 1.6 (p < 0.02)
IBP2 2.3 (p < 0.0001) Apolipoprotein E 1.7 (p < 0.0014) UCHL1 1.5 (not significant)
aSerum Amyloid A4 2.3 (p < 0.0007) CNDP1 1.7 (p < 0.0039) Prosaposin 1.5 (not significant)
aPro-orexin 2.2 (p < 0.0017) Apolipoprotein H 1.7 (p < 0.01) Vitamin D binding protein 1.5 (p = 0.05)
aCarboxypeptidase E 2.2 (p < 0.0001) aProsaposin 1.7 (p < 0.02) Chitinase-3-like protein 1 1.4 (not significant)
Apolipoprotein H 2.2 (p < 0.0001) S100B 1.7 (p < 0.031) GM2 Activator Protein 1.3 (not significant)
Chitinase-3-like protein 1 2.2 (p < 0.0012) Ubiquitin 1.6 (p < 0.011) S100B 1.3 (not significant)
aprosaposin 2.1 (p < 0.0001) Insulin-like growth factor 2 1.6 (p < 0.0052) Apolipoprotein E 1.2 (not significant)
aUCHL1 2 (p < 0.0108) Cystatin C 1.6 (p < 0.002) CNDP1 1.2 (not significant)
aLAMP1 2 (p < 0.0003) Vitamin D binding protein 1.6 (p < 0.01) Clusterin 1.2 (not significant)
Cystatin C 1.9 (p < 0.0001) IBP2 1.6 (p < 0.0052) Cystatin C 1.2 (not significant)
Vitamin D binding protein 1.9 (p < 0.0001) LAMP1 1.5 (not significant) Transferrin 1.2 (not significant)
Transthyretin 1.8 (p < 0.0001) aCarboxypeptidase E 1.5 (p < 0.0097) LAMP1 1.1 (not significant)
Insulin-like growth factor 2 1.8 (p < 0.0015) aTREM 2 1.5 (p < 0.0062) Carboxypeptidase E 1.1 (not significant)
aTREM 2 1.8 (p < 0.0003) aLSAMP 1.5 (p < 0.0004) TIMP1 1.1 (not significant)
aLSAMP 1.8 (0.0009) Pro-orexin 1.4 (not significant) Insulin-like growth factor 2 1.1 (not significant)
ENPP2 a1.7 (p < 0.0001) Clusterin 1.4 (p < 0.0102) TREM 2 1.1 (not significant)
S100B 1.7 (p < 0.0037) TIMP1 1.4 (p < 0.0055) IBP2 1.1 (not significant)
Clusterin 1.6 (p < 0.0001) Transferrin 1.4 (p < 0.01) Transthyretin 1 (not significant)
Transferrin 1.4 (p < 0.0015) Transthyretin 1.1 (not significant) Ubiquitin 0.9 (not significant)
TIMP1 1.3 (p < 0.018) ENPP2 1 (not significant) ENPP2 0.8 (not significant)
  1. The fold-change in the expression of each protein biomarker relative to the control group, are shown in the second column with their p value determined by Mann-Witney U test shown in parenthis below it
  2. aDenotes new markers not described previously as being potential neurodegenerative markers